View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 5, 2018updated 22 Nov 2021 7:36am

GW Pharmaceuticals launches cannabis-based drug Epidiolex in US

UK-based GW Pharmaceuticals and its US division Greenwich Biosciences have launched an oral solution of cannabis-based drug Epidiolex in the US to treat seizures in Lennox-Gastaut syndrome (LGS) or Dravet syndrome patients aged two years and above.

UK-based GW Pharmaceuticals and its US division Greenwich Biosciences have launched an oral solution of cannabis-based drug Epidiolex in the US to treat seizures in Lennox-Gastaut syndrome (LGS) or Dravet syndrome patients aged two years and above.

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

Epidiolex is said to be the first plant-derived cannabidiol (CBD) pharmaceutical formulation in the country. The US Food and Drug Administration (FDA) accepted the company’s new drug application (NDA) in January this year and granted approval in June.

The regulatory agency also granted orphan drug designation for Epidiolex to treat seizures caused due to tuberous sclerosis complex (TSC).

GW is now seeking approval from the European Medicines Agency (EMA).

GW Pharmaceuticals CEO Justin Gover said: “We are delighted to announce that Epidiolex is now available by physician prescription as a new treatment option for patients with LGS and Dravet syndrome, two of the most difficult-to-treat forms of childhood-onset epilepsy.

“Epidiolex is now available as a new treatment option for patients with LGS and Dravet syndrome, two of the most difficult-to-treat forms of childhood-onset epilepsy.”

“Because these patients have historically not responded well to available seizure medications, there has been a dire need for new therapies that aim to reduce the frequency and impact of seizures.”

The drug was evaluated in three randomised, controlled Phase III clinical trials and one open-label extension study conducted as part of the EPIDIOLEX clinical development programme.

Data showed that Epidiolex significantly minimised the drop seizures frequency in LGS patients and convulsive seizures in Dravet syndrome patients when given in combination with other antiepileptic therapies.

The most common adverse reactions associated with the drug were somnolence, decreased appetite, diarrhoea, transaminase elevations, fatigue, rash, insomnia and infections.

Currently, GW is evaluating Epidiolex in a separate Phase III clinical development programme for treating seizures associated with TSC. Greenwich Biosciences will market the drug in the US.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology